Incivek™ (Telaprevir) – Your Questions Answered
Share
Follow Us
The Editors at Hepatitis Central
May 23, 2011
With the approval of Incivek™ (telaprevir) for the treatment of those with Hepatitis C, genotype 1, and the potential to cut treatment time to just 24 weeks, many questions arise. Here we have summarized some of these questions.
by Editors at Hepatitis-Central.com
With the approval of a new treatment option for those with Hepatitis C genotype 1 there is bound to be questions. Based on the information provided by Vertex, developer of Incivek™, we have provided summaries for many of the questions that are being asked. Learning more about this new combination therapy and discussing this information with your healthcare provider are essential.
Simply click on any of the links below for more details:
- What is Incivek™ (telaprevir)?
- What is the dosage for Incivek™ (telaprevir)?
- Does the dosage and administration of Incivek™ (telaprevir) differ for various people?
- When is Incivek™ contraindicated?
- What types of adverse reactions were reported when taking Incivek™?
- Are there any other warnings one should know regarding Incivek™ combination therapy?
- At what point would one know the Incivek™ combination therapy is not working?
- Can those co-infected with HIV and Hepatitis C begin Incivek™ combination therapy?
- When can I get a prescription for Incivek™ (telaprevir)?
- How can I get assistance paying for Incivek™ (telaprevir)? Is Incivek™ covered by insurance?
